Updated:
Shanghai Fosun Pharmaceutical (Group)
Founded in 1994 and listed on both the Shanghai and Hong Kong stock exchanges, Shanghai Fosun Pharmaceutical (Group) evolved as the core healthcare vehicle...
Shanghai Fosun Pharmaceutical (Group)
Founded in 1994 and listed on both the Shanghai and Hong Kong stock exchanges, Shanghai Fosun Pharmaceutical (Group) evolved as the core healthcare vehicle within Guo Guangchang's Fosun International. The firm's controlling shareholder remains Fosun International, with Board Chairman Chen Yuqing and CEO Liu Yi leading day-to-day operations. The group's founding mandate was to build a domestic pharmaceutical manufacturing base; three decades later, it covers the full industry chain including direct operations in pharmaceuticals, medical devices, and diagnostics, plus an indirect reach into distribution through its equity stake in Sinopharm Group. The firm's deployment model is unusual for a corporate strategic: it operates direct subsidiaries that discover, develop, and manufacture treatments while maintaining an in-house venture and M&A function that acquires new pipeline assets. Its portfolio includes Henlius, the biologics subsidiary behind HANLIKANG, China's first biosimilar, and Zercepac, the first China-Europe dual-approved monoclonal antibody. The company also commercialized YIKAIDA, China's first approved CAR-T cell therapy, and introduced the da Vinci surgical robot platform to the Chinese market. Geographically, Fosun Pharma has commercialized products in over 90 countries, with specific operational footprints in the United States, Europe, India, Southeast Asia, and Africa. With 40,603 employees globally as of 2025, the firm maintains its headquarters in Shanghai's Fosun Technology Park and an additional office in Hong Kong's Manulife Place. Guo Guangchang anchors the entity within a wider community of influence through his membership in YPO's North Asia chapter and his leadership role at the Zhejiang Chamber of Commerce in Shanghai. The firm's recent focus marries artificial intelligence with drug discovery and commercialization, part of a stated 2025-onward strategy of "deep internationalization and comprehensive embrace of AI" (per the firm, 2025). The structural differentiator is the integration of a global product-licensing engine with a captive domestic distribution alliance. By holding a significant stake in Sinopharm Group, the dominant state-backed pharmaceutical distributor, Fosun Pharma secures market access for its imported and self-developed drugs in a way that independent biotechs cannot replicate. This distribution advantage, combined with a direct manufacturing base and a public-company balance sheet, creates a hybrid corporate venture-and-operations architecture rare outside of large Japanese and Indian pharmaceutical houses.
General information
Firm type
Corporate Investor
Year founded
1994
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
No. 1289 Yishan Road, Shanghai, China
Additional offices
5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong
Principals
Guo Guangchang
Co-founder and Chairman of Fosun International; ultimate beneficial owner
Chen Yuqing
Chairman of the Board
Liu Yi
CEO and President
Sector focus
Frequently asked questions
Who controls investment decisions at Shanghai Fosun Pharmaceutical?
Strategic investment and M&A decisions flow through CEO Liu Yi and the board chaired by Chen Yuqing, with ultimate oversight from Fosun International Chairman Guo Guangchang as the controlling shareholder's founder. The firm maintains a dedicated 'Business Development' function for new technology and project collaborations, reachable via its public-facing investment cooperation channels.
How does Fosun Pharma source its drug pipeline and technology platforms?
The firm combines internal R&D with a systematic in-licensing and acquisition model. It identifies clinical-stage assets globally—particularly in oncology and immunology—and brings them into China for development and commercialization, leveraging its CAR-T, antibody-drug conjugate (ADC), and small-molecule platforms. Its partnership with Gilead Sciences to market YIKAIDA in China exemplifies this model.
Does Fosun Pharma operate as a pure pharmaceutical company or as a corporate venture investor?
It functions as a hybrid. While most revenue comes from manufacturing and selling its own drugs, the firm actively acquires equity stakes in external biotech platforms and co-develops products. Investments are held either on its own balance sheet or through subsidiaries like Henlius, which itself operates a distinct drug-development business with Fosun Pharma as the majority holder.
What role does the Sinopharm distribution stake play in Fosun Pharma's business?
Fosun Pharma holds a significant minority interest in Sinopharm Group, China's largest pharmaceutical distributor. This relationship provides the firm preferential placement for its own products and those it licenses from global partners, creating a distribution moat that accelerates market penetration for newly approved drugs across Chinese hospitals and pharmacies.
Which sectors does the firm explicitly target for investment and development?
The group concentrates on innovative drugs for oncology, immune-inflammatory diseases, and neurodegenerative disorders, while expanding into chronic disease and rare disease categories. On the technology-platform side, it is building capabilities in antibody/ADC development, cell therapy, radiopharmaceuticals, and small nucleic acid therapeutics.
How is the Shanghai Fosun Foundation structured relative to the operating business?
The Shanghai Fosun Foundation operates as a separate philanthropic entity under the broader Fosun ecosystem, funded by corporate and personal donations. It maintains its own permanent art collection and funds public-access projects at the Bund Finance Center, including the Counter Sky Garden, without drawing on Fosun Pharma's pharmaceutical working capital.
What is Fosun Pharma's geographic revenue split and international strategy?
While China remains its core market, the firm has direct commercial operations in the US, Europe, India, Southeast Asia, and Africa, with products sold in over 90 countries. Its international strategy focuses on exporting biosimilars and innovative drugs that have secured dual China-foreign approvals, such as Zercepac in Europe, while distributing mRNA vaccines and anti-malarials like Artesun through global health channels.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: